PTC (NASDAQ: PTC) will release its fiscal 2026 first quarter and on Wednesday, February 4 th after the stock market closes.

PTC (PTC) is drawing investor attention after a recent stretch of weaker share performance, with the stock showing declines ...

Conference draws participants from more than 60 countries; demand for leadership programs reaches capacity From sold ...

Founded in 1985, the Boston, Massachusetts-based PTC Inc. (PTC) provides software solutions and services globally that aid ...

Shares of PTC Therapeutics jumped 15% on Jan. 8 to $20.65, after the maker of Duchenne muscular dystrophy drug Emflaza told investors it expected its revenues to rise 135% year over year for 2017 and ...

PTC Therapeutics (PTCT) beats 2025 revenue guidance, details Evrysdi royalties and Sephience growth, and sets 2026 outlook.

Welcoming back in-person delegates to its LiveWorx conference for the first time since the pre-pandemic days of 2019, and noting that the company finds itself in one of the greatest periods of change ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2026. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at ...

Shares of PTC Inc. PTC shed 1.18% to $171.52 Friday, on what proved to be an all-around great trading session for the stock ...

PTC Therapeutics faces pivotal FDA decisions for Translarna and Vatiquinone, with outcomes uncertain while both approvals are potentially transformative for long-term revenues. The Novartis ...